- Brenig Therapeutics Announces Appointments of David L. Lucchino as CEO and Tien Dam, M.D., as Chief Medical Officer, Expands Pipeline
- Brenig Therapeutics Announces the Initiation of First-in-Human Clinical Trial of BT-267, a Best-in-Class LRRK2 Inhibitor for Parkinson’s Disease
- Brenig Therapeutics Announces $65 Million Series A Financing to Advance Leading Pre-Clinical Parkinson’s Disease Pipeline
- Brenig Therapeutics Presented New Data for the Best-in-Class LRRK2 Inhibitor Targeting Parkinson’s Disease at the ACS Spring 2024 Conference
- Brenig Therapeutics Unveils Superior Safety Profile of LRRK2 Inhibitor BT-0267 with Exceptional CSF/Plasma Ratio at Future of Parkinson’s Disease Conference
